---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-262264"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2026-06-08T22:23:37+00:00"
generated_at: "2026-06-09T10:08:21.466256+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics stockholders elect three Class I directors and ratify auditor at 2026 annual meeting

## Summary
- All three Class I director nominees elected: Kabeer Aziz (13.5M for, 4.0M withheld), Gilbert Marks (15.9M for), Rob Readnour (15.9M for).
- Ratification of PricewaterhouseCoopers as auditor for fiscal 2026 approved with 22,724,674 for, 13 against, 16,848 abstain.
- Approximately 63.18% of outstanding shares (22.7M of 35.99M) represented at meeting, constituting quorum.

## SEC filing metadata
- accession: 0001193125-26-262264
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2026-06-08T22:23:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/antx-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-262264
- JSON: https://secwatch.observer/filing/0001193125-26-262264.json
- Plain text: https://secwatch.observer/filing/0001193125-26-262264.txt

## Key facts
- Shareholder Votes
  AN2 Therapeutics, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions 22,724,674 13 16,848
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm
- Shareholder Votes
  AN2 Therapeutics, Inc. shareholders approved Election of the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: 1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Kabeer Aziz 13,547,536 3,958,874 5,235,125 Gilbert Lynn Marks, M.D. 15,947,854 1,558,556 5,235,125 Rob Readnour, Ph.D. 15,920,563 1,585,847 5,235,125
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.